RETRACTED: CSF p-tau as a potential cognition impairment biomarker in ALS

Gong, Zhongying; Gao, Lina; Lu, Yi; Wang, Zhiyun

doi:10.3389/fneur.2022.991143

ORIGINAL RESEARCH article

Front. Neurol., 01 November 2022

Sec. Dementia and Neurodegenerative Diseases

Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.991143

This article is part of the Research Topic Advances in Integrative Medicine for Neurodegenerative Diseases: From Basic Research to Clinical Practice View all 11 articles

RETRACTED: CSF p-tau as a potential cognition impairment biomarker in ALS

Retracted

A retraction of this article was approved in:

Retraction: CSF p-tau as a potential cognition impairment biomarker in ALS
1. Read retraction

$\nZhongying Gong$ Zhongying Gong^*

Lina Gao

Yi Lu

Zhiyun Wang^*

Department of Neurology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Gong Z, Gao L, Lu Y and Wang Z (2022) CSF p-tau as a potential cognition impairment biomarker in ALS. Front. Neurol. 13:991143. doi: 10.3389/fneur.2022.991143

Received: 11 July 2022; Accepted: 11 October 2022;
Published: 01 November 2022; Retracted: 04 March 2024.

Edited by:

Shaonan Liu, Guangdong Provincial Hospital of Chinese Medicine, China

Reviewed by:

Antonio Giuliano Zippo, National Research Council (CNR), Italy
Lezanne Ooi, University of Wollongong, Australia
Dzung Do-Ha, University of Wollongong, Australia, in collaboration with reviewer LO

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.